ACLARIS THERAPEUTICS INC's ticker is ACRS and the CUSIP is 00461U105. A total of 100 filers reported holding ACLARIS THERAPEUTICS INC in Q1 2021. The put-call ratio across all filers is 0.65 and the average weighting 1.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $6,570,520 | -36.4% | 9,592 | -99.0% | 0.79% | -51.9% |
| Q2 2023 | $10,333,321 | -21.2% | 996,463 | -38.5% | 1.65% | -44.7% |
| Q1 2023 | $13,117,636 | +6206.6% | 1,621,463 | +13274.0% | 2.98% | +10925.9% |
| Q1 2022 | $208,000 | +33.3% | 12,124 | +12.4% | 0.03% | +17.4% |
| Q4 2021 | $156,000 | -79.7% | 10,785 | -74.7% | 0.02% | -57.4% |
| Q3 2021 | $770,000 | -51.2% | 42,712 | -52.4% | 0.05% | -57.5% |
| Q2 2021 | $1,577,000 | -66.7% | 89,788 | -52.3% | 0.13% | -20.6% |
| Q1 2021 | $4,742,000 | +36.7% | 188,200 | -64.9% | 0.16% | +4.6% |
| Q4 2020 | $3,468,000 | – | 535,800 | – | 0.15% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Foresite Capital Management V, LLC | 1,258,243 | $8,618,965 | 13.75% |
| Foresite Capital Management IV, LLC | 2,808,034 | $19,235,033 | 10.68% |
| Bain Capital Life Sciences Investors, LLC | 3,400,000 | $23,290,000 | 2.60% |
| GREAT POINT PARTNERS LLC | 1,691,768 | $11,588,611 | 2.11% |
| Samsara BioCapital, LLC | 696,171 | $4,768,771 | 1.46% |
| Altium Capital Management LP | 403,000 | $2,760,550 | 1.44% |
| BVF INC/IL | 7,064,736 | $48,393,442 | 1.30% |
| Aisling Capital Management LP | 434,455 | $2,976,017 | 1.23% |
| GREAT POINT PARTNERS LLC | 700,000 | $4,795,000 | 0.87% |
| VR Adviser, LLC | 1,040,754 | $7,129,165 | 0.75% |